What Can you Expect in 2026?
In 2026, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA's new mechanism pathway reshaping strategy, the decisions made now will determine which assets reach patients.
The 7th Genome Editing Therapeutics Summit is the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting. At this year's summit you will:
- Delve into extrahepatic delivery strategies to widen your technology across multiple disease indications
- Learn from clinical companies building robust IND packages to fast-track development
- Evaluate immunogenicity and off-targeting case studies to sharpen your therapy's safety profile
Unmissable Event Highlights
Tackling Off-Targeting & Immunogenicity Head-On to Build a Safety Profile Regulators Trust
Explore how leading companies are reducing off-target toxicity, leveraging sequencing-based methods to assess gRNA purity and genomic instability, and engineering vectors to overcome immune-mediated clearance and side effects, so nothing stands between your therapy and its target.
Hear from:
Unlocking New Genome Editing Technologies & Extrahepatic Delivery to Expand the Therapeutic Potential of Applied Genome Editing
Discover how peers are redirecting LNP and AAV vectors to target tissue of interest, leveraging diverse nuclease platforms and next-generation tools like prime and base editors. Apply these approaches to open your platform up to a wider range of disease indications.
Hear from:
Bridging the Preclinical to Clinical Gap to Move Your Genome Editing Therapy Closer to Patients
Hear how leading companies are anchoring preclinical programs on human genetic insights, aligning endpoints with target product profiles, and applying genome editing to pioneering applications like xenotransplantation to give your program the translational foundation it needs to advance with confidence.
Hear from:
Addressing Manufacturing Scalability & CDMO Collaboration to Protect Product Quality at Every Stage
Explore with industry peers how to streamline analytical collaboration, optimize CDMO partnerships and develop flexible guide RNA manufacturing approaches. Leave with practical strategies to ensure your therapy reaches patients without compromising on quality or consistency.
Hear from:
Explore the Full Event Guide
- 3 days of content to find the sessions your program needs most
- 50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage
- 80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers
- 64% in vivo & 36% ex vivo agenda to fit your route of delivery
- See how Intellia, Beam Therapeutics & others closest to approval are contributing to the meeting
Attending Companies Include
Explore the Agenda
See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.
Partner With Us
Put your solutions in front of the genome editing decision-makers actively looking for them.
Join Genome Editing Experts
Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.